Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
Crossref DOI link: https://doi.org/10.1186/s12958-016-0164-y
Published Online: 2016-06-10
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Strowitzki, Thomas
Kuczynski, Waldemar
Mueller, Arnd
Bias, Peter
Funding for this research was provided by:
This study was supported by BioGeneriX AG, now known as Merckle GmbH, a member of the Teva group.